The dual clinical and mechanistic effects of PTX, particularly its ability to reduce inflammation, oxidative stress, and endothelial damage through mechanisms such as Klotho upregulation and ROS reduction, highlight its potential as a more targeted therapy for DKD patients at risk of ASCVD. The gene discussed is KL; the disease is diabetic kidney disease.